A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose "Wearing-Off"

Trial Profile

A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose "Wearing-Off"

Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Tozadenant (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Biotie Therapies Corp.
  • Most Recent Events

    • 01 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 24 Apr 2015 New trial record
    • 23 Apr 2015 This open-label phase III safety trial will be initiated if the first phase III trial of tozadenant meets its primary endpoint, according to a Biotie Therapies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top